NewTimeSpace News: On 21 August 2026, Tyligand Bioscience Ltd. re-submitted a listing application to the HKEX Main Board, with CITIC SEC as the sole sponsor; the Company, founded in 2017, is a clinical-stage biopharmaceutical company focused on oncology, with core product TSN1611, an oral KRAS G12D inhibitor, in Phase 2 trials in the US and China; it has communicated with the FDA on the registrational Phase 3 MRCT and plans to seek NMPA approval for participation in China.
NewTimeSpace News: Mech-Mind Robotics disclosed in an announcement on August 24 that the Company has launched its global offering with an initial offer of approximately 23.1406 million H shares, including around 1.1570 million shares for Hong Kong public offering, at a maximum offer price of HK$101.70 per share.
NewTimeSpace News: SHEIN Group disclosed in an announcement on August 24 that the Company has launched its global offering with an initial offer of approximately 280 million Class B shares, including around 27.9993 million shares for Hong Kong public offering, at a maximum offer price of HK$49.50 per share.
NewTimeSpace News: Beijing Junzheng disclosed in an announcement on August 21 that the offer price for the global offering of its H-shares has been fixed at HK$100 per share (excluding transaction fees). The H-shares are expected to be listed on the Main Board of the Hong Kong Stock Exchange on August 25, 2026.
NewTimeSpace News: On 20 August 2026, Medcaptain Medical Technology passed the HKEX listing hearing, with Morgan Stanley and Huatai International as joint sponsors; the Company is a global medical device provider covering life support, minimally invasive intervention and in vitro diagnostics, ranking first in China's infusion workstation market from 2018 to 2025, and turned profitable in 2025 with a net profit of RMB 50.7 million.
NewTimeSpace News: On 20 August 2026, PANACRO (Hangzhou) Pharmaceutical Consulting Co., Ltd. refiled for a Hong Kong listing, with China Industrial Securities International and ICBC International as joint sponsors; the Company is a clinical CRO headquartered in Hangzhou, ranking 14th among Chinese companies by 2025 clinical CRO service revenue (0.7% share), with digital systems shortening bid preparation time by approximately 30% and a gross margin of 38.9% above industry average.
NewTimeSpace News: On 20 August 2026, the subscription period of INGENIC SEMICONDUCTOR (03223.HK) ended, with market data showing total margin financing of HKD 220.94558 billion and the public offer oversubscribed by 685.93 times; the offer price does not exceed HKD 102.80 per share in lots of 100 shares, with listing expected on 25 August.
NewTimeSpace News: On 20 August 2026, the Hong Kong listing application of Hangzhou GreenCloud Software Co., Ltd. filed on 20 February 2026 has lapsed after exceeding the six-month validity period, with CICC as the original sole sponsor; the Company is the largest PMS provider in China's hospitality digitalisation industry, with market shares of 16.8% by sales and 16.3% by rooms covered in 2024, serving over 37,000 hotels.
NewTimeSpace News: On 20 August 2026, Junlebao Dairy Group refiled for a Hong Kong listing, with CICC and Morgan Stanley as joint sponsors; the Company is a national dairy company ranking third in China by 2025 retail sales (4.3% share) and first in the low-temperature liquid milk market (15.6%), with "Jianchun" as the No.1 low-temperature yogurt brand and "Yuexianhuo" as the No.1 fresh milk brand.
NewTimeSpace News: On 20 August 2026, TINCI (002709.SZ) announced that its H-share issuance has obtained the CSRC filing for overseas offering and listing, planning to issue up to 412,760,200 overseas listed ordinary shares for listing on the Hong Kong Stock Exchange; the filing notice is valid for 12 months, and updated filing materials are required if the listing is not completed within that period.
NewTimeSpace News: On 19 August 2026, SKG Health Technologies Co., Ltd. refiled for a Hong Kong listing, with CITIC Securities International as the sole sponsor; the Company is a health technology company ranking first among domestic participants in China's smart soothing wearable device industry by 2025 GMV with a market share of 21.6%, holding 1,554 registered patents globally.
NewTimeSpace News: On 19 August 2026, KEYMED BIO-B (02162.HK) announced that its board resolved to propose an issuance of ordinary shares to be listed on the STAR Market of the Shanghai Stock Exchange and traded in RMB, subject to market conditions, further board approval, shareholders' approval at a general meeting and necessary regulatory approvals; no application has been made to regulators as of the announcement date, and the issuance may not proceed.
NewTimeSpace News: On 19 August 2026, according to HKEX disclosure, Direct Drive Tech Limited filed its listing application with CITIC Securities as the sole sponsor; the Company is a direct-drive technology robot company, ranking first in China's consumer robot direct-drive power module industry (61.1% share) and second in the two-wheeled-footed robot industry (18.6%) by 2025 revenue, with the D1 being the world's first commercially launched modular two-wheeled-footed robot.
NewTimeSpace News: On 18 August 2026, Tianjin Chenxing Technology Co., Ltd. (formerly Tianjin Atomrobot Technology Co., Ltd.) refiled for a Hong Kong listing, with Huatai International as the sole sponsor; the Company is a high-speed industrial robot enterprise, ranking first in China's delta robot market (20.4% share) and second globally (7.7%) by 2025 shipments, with robot sales revenue of RMB 163.3 million in 2025.
NewTimeSpace News: On 18 August 2026, Shenzhen Immunofoco Biotechnology Co., Ltd. (IMMUNOFOCO-B) re-filed its HKEX listing application with Huatai International as sole sponsor. Founded in 2020, the CAR-T cell therapy company's core product IMC002 (anti-CLDN18.2 CAR-T) is in a registration Phase III trial for advanced gastric cancer, with an IND submitted in June 2026 for first-line pancreatic cancer. The pipeline comprises eight additional candidates spanning both ex vivo and in vivo CAR-T platforms.
NewTimeSpace News: On 17 August 2026, the Hong Kong listing application of Shenzhen Hongyeji Geotechnical Technology Co., Ltd. filed on 15 February 2026 has lapsed after exceeding the six-month validity period, with CEB International as the original sole sponsor; the Company is the largest non-state-owned geotechnical engineering enterprise in South China and ranks first among non-state-owned enterprises participating in large-scale South China projects by 2024 revenue.
